Lumosa Therapeutics Co. Ltd.
- Address
- 4 F, No 3-2 Park St., Nangang Dist.
Sponsor Overview
Specializations
Neurology and Stroke
Research activity is centered on acute ischemic stroke, with attention to clinical outcomes relevant to cerebrovascular disease and brain ischemia.
- Acute ischemic stroke
- Cerebrovascular injury
- Neurological recovery
Clinical interest extends to treatment settings that address acute neurological events and the preservation of brain function after ischemic injury.
Acute Care and Emergency Medicine
The sponsor’s clinical focus includes urgent intervention in acute stroke care, where rapid management of ischemic events is central to patient care.
- Emergency stroke treatment
- Time-sensitive neurological care
- Acute vascular events
This area reflects interest in therapies intended for patients presenting with sudden onset of neurological deficits linked to impaired cerebral blood flow.
Therapeutic Development in Neurovascular Disease
Clinical research activity is directed toward the evaluation of LT3001 in the context of neurovascular disorders, with emphasis on treatment options for ischemic stroke.
- Neurovascular therapeutics
- Stroke-directed drug development
- Ischemia-related treatment
The therapeutic domain is focused on pharmacological approaches relevant to restoring or protecting neurological function after vascular occlusion.
Clinical Safety and Patient Tolerability
Research interest includes the assessment of safety and tolerability in people with acute ischemic stroke, supporting the clinical characterization of treatment use in a vulnerable population.
- Safety evaluation
- Tolerability assessment
- Acute neurological patient care
These activities are aligned with clinical questions surrounding the use of investigational therapies in the immediate post-stroke setting.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS) |  Czechia Germany Greece Italy Portugal Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 18 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
18 centres- Address
- Weisse Mauer 52, 06217 Merseburg
- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Carrer De San Quinti 89, 08041 Barcelona
- Address
- Piazzale Giorgio Menghini 1, 06129 Perugia
- Address
- Avinguda De Franca S/n, 17007 Girona
- Address
- Calle De Manuel De Falla 1, 28222 Majadahonda
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Lumosa Therapeutics Co. Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.